XW0M3KA
Introduction Coronary Artery, Four or More Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Three Balloons, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | M Coronary Artery, Four or More Arteries |
| Approach | 3 Percutaneous |
| Device | K Paclitaxel-Coated Balloon Technology, Three Balloons |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Coronary Artery, Four or More Arteries
This code applies when a New Technology substance is introduced into four or more coronary arteries in one procedural episode, representing the most extensive pattern of coronary involvement captured by these introduction codes. Because the coronary tree branches into numerous named and unnamed segments beyond the three main trunks, reaching four or more vessels typically signals diffuse atherosclerotic or microvascular disease rather than isolated single-vessel pathology. Precise vessel counting is essential for correct code selection, distinguishing this from the three-artery variant, and clinicians should document each treated segment individually in the operative note. Because these are New Technology codes, the specific agent or device must also be identified, allowing data collection on how broadly diseased coronary anatomy responds to the emerging therapy across a larger vascular field.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Paclitaxel-Coated Balloon Technology, Three Balloons
This value specifies use of paclitaxel-coated balloon angioplasty involving three balloons during a single procedure to deliver drug coating across treated vessel segments. As with the related one-, two-, and four-or-more-balloon values, the distinction lies solely in balloon count documenting procedural extent, not in a different drug, device design, or clinical indication.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.